AVLN
Avalyn Pharma expands leased space under Boston deal.
Avalyn Pharma and CRISPR Therapeutics agreed to expand the total leased area to approximately 13,700 square feet. This amendment enhances operations at the Boston facility.
AVLN news
Latest 3 stories · newest Jul 1, 2026
AVLN
Avalyn Pharma completes enrollment of 375 patients in Phase 2b MIST trial
Avalyn Pharma announced completion of target enrollment in its Phase 2b MIST clinical trial evaluating AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis, with topline results expected in H2 2027. The milestone demonstrates strong investigator and patient demand for new PPF treatment opti…
AVLN
Avalyn Pharma reports Q1 2026 results, IPO raises $345M for pipeline advancement
Avalyn completed an upsized IPO raising $345 million gross proceeds and reported progress on three pulmonary fibrosis programs, with MIST Phase 2b enrollment on track for mid-2026 completion. The company has sufficient capital to fund operations into 2029, with clinical readouts expected across all …
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same AVLN feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/AVLN/newsSTART FREE